I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 3, 2006 Signature: _____ (Reza Mollaaghababa)

Docket No.: 022727-0129 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Jerome L. Ackerman et al.

Application No.: 10/532,156 Confirmation No.: 6179

Filed: November 7, 2005 Art Unit: N/A

For: RADIO FREQUENCY COIL AND CATHETER FOR SURFACE NMR IMAGING AND SPECTROSCOPY (AS AMENDED) Examiner: Not Yet Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56 (b).

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 141449, under Order No. 022727-0129.

Dated: October 3, 2006

Respectfully submitted,

By_____

Reza Mollaaghababa
Registration No.: 43,810
NUTTER MCCLENNEN & FISH LLP
World Trade Center West
155 Seaport Boulevard
Boston, Massachusetts 02210-2604
(617) 439-2514
(617) 310-9514 (Fax)
Attorney for Applicant

1565981.1

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	10/532,156-Conf. #6179
Filing Date	November 7, 2005
First Named Inventor	Jerome L. Ackerman
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	022727-0129

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	CA	Holt, DI, J. Magn Reson. 1979; 33: 183-197.	
	CB	Bottomley PA, Foster TB, Darrow RT. J Magn Reson. 1984; 59: 338.	
	CC	Chen CN, Holt DI, Sank VJ. J Magn Reson. 1983; 54: 324-327.	
	CD	Misic GJ, Hurst GC, Orlando PT. Society of Magnetic Resonance in Medicine, Fourth Annual Meeting, 1985, p. 1109.	
	CE	Libby, P. The molecular basis of the acute coronary syndromes. *Circulation*.. 91, 2844-2850 (1995).	
	CF	Mohiaddin, R.H., Firmin, D.N., Underwood, S.R., Abdulla, A.K., Klipstein, R.H., Rees, R.S. & Longmore, D.B. Chemical shift magnetic resonance imaging of human atheroma. *Br. Heart* J. 62, 81-89 (1989).	
	CG	Asdente, M., Pavesi, L., Oreste, P.L., Columbo, A., Kuhn, W. & Tremoli, E. Evaluation of atherosclerotic lesions using NMR microimaging. *Atherosclerosis*. 80, 243-253 (1990).	
	CH	Toussaint, J.F., Southern, J.F., Fuster, V. & Kantor, H.L. T2-weighted contrast for NMR characterization of human atherosclerosis. *Arterioscler. Thromb. Vasc. Biol.* 15, 1533-1542 (1995).	
	CI	Shinnar, M., Fallon, J.T., Wehrli, S., Levin, M., Dalmacy, D., Fayad, Z.A., Badimon, J.J., Harrington, M., Harrinton, E. & Fuster, V. The diagnostic accuracy of ex vivo magnetic resonance imaging for human atherosclerotic plaque characterization. *Arterioscler. Thromb. Vasc. Biol.* 19, 2756-2761 (1999).	
	CJ	Toussaint, J.F., Southern, J.F., Fuster, V. & Kantor, H.L. Water diffusion properties of human atherosclerosis and thrombosis measured by pulse field gradient nuclear magnetic resonance. *Arterioscler. Thromb. Vasc. Biol.* 17, 542-546 (1997).	
	CK	Pachot-Clouard, M., Vaufrey, F., Darrasse, L. & Toussaint, J.F. Megnetization transfer characteristics in atherosclerotic plaque components assessed by adapted binomial preparation pulses. *MAGMA*. 7, 9-15 (1998).	
	CL	Toussaint, J.F., LaMuraglia, G.M., Southern, J.F., Fuster, V. & Kantor, H.L. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human	

Examiner Signature		Date Considered	

PTO/SB/08a/b (07-06)
Approved for use through 09/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	2

Complete if Known	
Application Number	10/532,156-Conf. #6179
Filing Date	November 7, 2005
First Named Inventor	Jerome L. Ackerman
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	022727-0129

		atherosclerosis in vivo. Circulation. 94, 932-938 (1996).	
	CM	von Ingersleben, G., Schmiedl, U.P., Hatsukami, T.S., Nelson, J.A., Subramaniam, D.S., Ferguson, M.S. & Yuan, C. Characterization of atherosclerotic plaques a the carotid bifurcation: correlation of high-resolution MR imaging with histologic analysis: preliminary study. Radiographics. 17, 1417-1423 (1997).	
	CN	Schmitz, S.A., Coupland, S.E., Gust, R., Winterhalter, S., Wagner, S., Kresse, M., Semmler, W. & Wolf, K.J. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. *Invest. Radiol.* 35, 460-471 (2000).	
	CO	Yu, X., Song, S.K., Chen, J., Scott, M.J., Fuhrhop, R.J., Hall, C.S., Gaffney, P.J., Wickline, S.A. & Lanza, G.M. High-resolution MRI characterization of human thrombus using a novel fibrin-targeted paramagnetic nanoparticle contrast agent. *Magn. Reson. Med.* 44, 867-872 (2000).	
	CP	Schmitz, S.A., Taupitz, M., Wagner, S., Wolf, J.J., Beyersdorff, D. & Hamm, B. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J. Magn. Reson. Imaging. 14, 355-361 (2001).	
	CQ	Rubinson, K.A. & Boska, M. A novel topical probe for MRI - the flat, truncated line probe. Magn. Reson. Imaging. 13, 301-308 (1995).	
	CR	Kunz, K. & Luebbers, R. *The Finite Difference Time Domain Method for Electromagnetics. CRC Press catalog number 8657 (1994)*	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	